FDA Grants RMAT Designation for KYV-101 to Treat Patients With Progressive Myasthenia Gravis

Retrieved on: 2024-08-12 20:47:08

Tags for this article:

Click the tags to see associated articles and topics

FDA Grants RMAT Designation for KYV-101 to Treat Patients With Progressive Myasthenia Gravis. View article details on hiswai:

Summary

The FDA's grant of RMAT designation for KYV-101 by Kyverna Therapeutics highlights its potential impact in treating myasthenia gravis, an autoimmune disease, through CAR T cell therapy, advancing regenerative medicine.

Article found on: www.pharmacytimes.com

View Original Article